<DOC>
	<DOCNO>NCT01809379</DOCNO>
	<brief_summary>This trial aim assess efficacy safety intraperitoneal , aerosol , high-pressure chemotherapy woman recurrent ovarian cancer</brief_summary>
	<brief_title>Intraperitoneal Aerosol High-pressure Chemotherapy Women With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>This study aim investigate therapeutic efficacy PIPAC use doxorubicin cisplatin woman recurrent ovarian cancer disease progression peritoneal carcinomatosis . The primary objective study determine Clinical Benefit Rate ( CBR ) accord RECIST criterion three cycle PIPAC cisplatin doxorubicin .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>least 2 line previous chemotherapy recurrent ovarian cancer patient mobile inform consent ileus necessity parenteral nutrition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ovarian cancer , recurrent , chemotherapy , intraperitoneal</keyword>
</DOC>